Track Lantheus Holdings, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Lantheus Holdings, Inc. LNTH Open Lantheus Holdings, Inc. in new tab

76.10 USD
P/E
22.32
EPS
3.41
P/B
4.51
ROE
21.45
Beta
-0.14
Target Price
91.38 USD
Lantheus Holdings, Inc. logo

Lantheus Holdings, Inc.

🧾 Earnings Recap – Q3 2025

Lantheus reported a solid third quarter in 2025, showcasing resilience in its core PSMA PET franchise despite a slight dip in sales, alongside strategic leadership transitions and preparations for the upcoming F-18 PET formulation launch.

  • Q3 sales for PYLARIFY reached $240.6 million, reflecting a year-over-year decrease of 7%, but U.S. volumes showed a positive 3.3% increase.
  • The company announced a leadership transition with Mary Anne Heino stepping in as interim CEO post Brian Markison's retirement, ensuring continuity in strategic execution.
  • Lantheus is preparing for the expected launch of the new F-18 PSMA PET formulation in 2026, which aims to enhance production efficiency and patient access.
  • DEFINITY maintained a strong performance with over 6% year-over-year growth, underscoring its market leadership in ultrasound-enhancing agents.
  • The neurology franchise, especially Neuraceq, is positioned for growth driven by increasing demand in the Alzheimer's disease imaging market.
📅
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
Earnings dateApril 30, 2026
P/E22.32
EPS3.41
Book Value16.87
Price to Book4.51
Debt/Equity57.19
% Insiders2.040%
Growth
Revenue Growth0.04%
Earnings Growth-0.77%
Estimates
Forward P/E12.09
Forward EPS6.29
Target Mean Price91.38

DCF Valuation

Tweak assumptions to recompute fair value for Lantheus Holdings, Inc. (LNTH)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Lantheus Holdings, Inc. Logo Lantheus Holdings, Inc. Analysis (LNTH)

United States Health Care Official Website Stock

Is Lantheus Holdings, Inc. a good investment? Lantheus Holdings, Inc. (LNTH) is currently trading at 76.10 USD. Market analysts have a consensus price target of 91.38 USD. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 22.32. This valuation is generally in line with the broader market.

Earnings Schedule: Lantheus Holdings, Inc. is expected to release its next earnings report on April 30, 2026. The market consensus estimate for Forward EPS is 6.29.

Investor FAQ

Does Lantheus Holdings, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Lantheus Holdings, Inc.?

Lantheus Holdings, Inc. is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be April 30, 2026. The company currently has a trailing EPS of 3.41.

Company Profile

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. It also provides Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; PYLARIFY AI, an medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer; and flurpiridaz used to assess blood flow to the heart. In addition, it develops PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy to patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent for Tau tangles in Alzheimer's disease; LNTH-2401, a novel radiodiagnostic targeting the gastrin-releasing peptide receptor; LNTH-2402; LNTH-2403; LNTH-2404; LNTH-250; LNTH-2515; and LNTH-1363S, an fibroblast activation protein, alpha, copper-64 labeled PET imaging agent. It has collaboration agreements with GE Healthcare; Curium Pharma; POINT; Regeneron; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Exchange Ticker
NGM (Sweden) LNTH
FRA (Germany) 0L8.F

Dividends

Historical Split Corporate Actions

Trades
Trade History
No trades yet
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion